Background
Varenicline, a nicotinic partial agonist, selectively reduces ethanol- versus sucrose-maintained behavior when tested in separate groups, yet like the indirect serotonin agonist fluvoxamine, this selectivity inverts when ethanol and food are concurrently available.
Materials and Methods
Here we extend these findings by examining varenicline and fluvoxamine effects under a multiple concurrent schedule where food and ethanol are concurrently available in different components: Component1 where the food fixed-ratio was 25 and Component2 where the food fixed-ratio was 75. The ethanol fixed-ratio was always 5, and food-maintained responding predominated in Component1 while ethanol-maintained responding predominated in Component2. In a second experiment, varenicline effects were assessed under a multiple schedule where food, then ethanol, then food was available in separate 5-min components with fixed-ratios of 5 for each reinforcement.
Results
In the multiple concurrent schedule, varenicline was more potent at reducing food- versus ethanol-maintained responding in both components, and reduced ethanol-maintained responding more potently during Component1 (when food was almost never earned) than in Component2 (where food was often earned). Fluvoxamine was similarly potent at reducing food- and ethanol-maintained responding. Under the multiple schedule, varenicline, like fluvoxamine, more potently decreases ethanol- versus food-maintained responding when only food or ethanol are available in separate components.
Conclusions
These results demonstrate that selective effects on drug- versus alternative-maintained behavior depend on the schedule arrangement, and assays in which ethanol or an alternative is the only programmed reinforcement may overestimate the selectivity of treatments to decrease ethanol self-administration. Thus, selective effects obtained under one assay may not generalize to another. Better understanding the behavioral mechanisms responsible for these results may help to guide pharmacotherapeutic development for substance use disorders.